- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | CARSGEN-B Opens 6.48% Lower on Net Proceeds of HKD462M from Share Placement | 2 | AASTOCKS | ||
| Fr | CARSGEN-B Places Shares at 9.49% Discount via Top-up Placement; Net Proceeds HKD462M | 1 | AASTOCKS | ||
| Fr | CARSGEN-B (02171): PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 27.04. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT0596 AND CT1190B ACCEPTED FOR POSTER PRESENTATION AT 2026 EHA ANNUAL CONGRESS | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR, ... | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): ANNUAL REPORT 2025 | - | HKEx | ||
| 09.03. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE 2019 EQUITY INCENTIVE PLAN | 1 | HKEx | ||
| 09.03. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST UNDER THE SOUTHBOUND STOCK CONNECT | 1 | HKEx | ||
| 06.03. | CARsgen Therapeutics Announces 2025 Annual Results | 342 | PR Newswire | SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| 06.03. | CARSGEN-B (02171): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ... | - | HKEx | ||
| 24.02. | CARSGEN-B (02171): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.02. | CARsgen to Expand Commercial Manufacturing Base in Shanghai | 1 | Contract Pharma | ||
| 13.02. | CARsgen Therapeutics: CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai | 183 | PR Newswire | SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 13.02. | CARSGEN-B (02171): DISCLOSABLE TRANSACTION - ENTERING INTO THE STRATEGIC COOPERATION AGREEMENTS | 1 | HKEx | ||
| 26.01. | CARSGEN-B (02171): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | 2 | HKEx | ||
| 23.01. | CARSGEN-B (02171): (REVISED) NEXT DAY DISCLOSURE RETURN | - | HKEx |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RELAY THERAPEUTICS | 12,070 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported... ► Artikel lesen | |
| NUVALENT | 101,00 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,27 | 0,00 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| ERASCA | 10,320 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,330 | 0,00 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| DYNE THERAPEUTICS | 15,920 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | - Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,300 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 19,500 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,850 | 0,00 % | Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now | ||
| PRAXIS PRECISION MEDICINES | 321,05 | +0,14 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 26,030 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) | ||
| COGENT BIOSCIENCES | 31,260 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| ABSCI | 4,630 | 0,00 % | Speicher und Bürgerenergie prägen ABSI-Jahrestagung in Neuötting | Auf der 33. Jahrestagung der Arbeitsgemeinschaft Bayerischer Solarinitiativen (ABSI) diskutierten rund 240 Fachleute über die zukünftige Rolle von Stromspeichern und Bürgerenergie. Im Zentrum stand... ► Artikel lesen | |
| TYRA BIOSCIENCES | 33,750 | -0,09 % | Wolfe Research initiates Tyra Biosciences stock at Peerperform | ||
| SUMMIT THERAPEUTICS | 15,860 | +0,06 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) |
CARSGEN THERAPEUTICS HOLDINGS LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.